Drug Profile
UAI 101
Alternative Names: UAI-101Latest Information Update: 19 Nov 2021
Price :
$50
*
At a glance
- Originator Ahn-Gook Pharmaceutical
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 01 Nov 2021 Preclinical development in Diabetes mellitus are ongoing in South Korea (Ahn-Gook Pharmaceutical pipeline, November 2021)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Diabetes-mellitus in South Korea
- 22 Aug 2017 Preclinical trials in Diabetes mellitus in South Korea (unspecified route) (Ahn Gook Pharmaceutical pipeline, August 2017)